The Shifting Landscape of p53abn Endometrial Cancers: a Review of the Prognostic and Predictive Impact and Current Therapeutic Directions

Table 1. p53abn important features (IHC – immunohistochemistry, NGS – next generation sequencing, RFS – recurrence free survival, EC – endometrial cancer, OS – overall survival)

Author(s) :

Angelo Anater

Medical Oncology Department, Oncohelp Clinic, Timișoara, Romania

Corresponding author: Angelo Anater, Email:

Published: III, 2, 1 October 2023, 1 - 15 DOI: 10.53011/JMRO.2023.02.02

Open Access

Full text


October 1, 2023 0 Comments


The major stepping stone laid towards the identification of high-risk endometrial cancers was made by the Cancer Genome Atlas in 2013 when the four distinct molecular subtypes were initially described. This hugely improved risk stratification for women with endometrial cancer and ignited a major interest which led to further research on the prognostic and predictive value of molecular subtyping. Through the elaboration of ProMisE, molecular risk assignment using surrogate markers became practical and accessible to most pathology laboratories. The p53abn molecular subtype of endometrial cancer is responsible for the worst outcomes. This review aims to provide an in-depth understanding of the characteristics of these aggressive ECs, summarizing up-to-date literature regarding the prognostic and predictive implications, as well as present and future treatment directions

Notify of
Inline Feedbacks
View all comments